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613Abstracts
whether this signiﬁcant relation is still present after
receiving treatment. If this relation is absent potential
mechanisms (e.g. coping style) that could explain dis-
crepancies will be investigated.
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OBJECTIVES: To model the 1-year cost-utility of
rabeprazole and esomeprazole “on demand” (prn) treat-
ment for symptomatic gastro oesophageal reﬂux disease
from the perspective of the UK National Health Service.
METHODS: Data relating to treatment discontinuation
due to inadequate heartburn control were extracted from
two clinical trials; one comparing rabeprazole 10mg with
placebo prn and the other comparing esomeprazole 
20mg, 40mg and placebo prn. Survival data (proportion
of patients continuing therapy) were ﬁtted to Weibull
functions, and adjusted for comparability according to
placebo data. Data from the trials on drug intake, use of
antacids as rescue medication and severity of heartburn
symptoms were also used for the analysis. Health care
resource utilization included annual frequency of general
practitioner and gastroenterologist consultation and of
upper GI endoscopy, annual number of drug prescriptions
and pharmacy dispensing fees. These were priced accord-
ing to the latest NHS costs. Health state utilities were
derived from a study that assessed EQ-5D utilities in 1003
patients with GERD, and related utility scores to dura-
tion and severity of symptoms. A probabilistic model was
employed that sampled from Weibull distributions for
survival time, assigned Poisson distributions to annual
frequency of events, Beta distributions to utilities and
Dirichlet distribution to severity of heartburn. RESULTS:
The mean total costs of therapy with rabeprazole 10mg,
esomeprazole 20mg and 40mg were £93, £103, and
£121, respectively. The associated utility scores were,
respectively, 0.866, 0.861 and 0.860. CONCLUSIONS:
For non-erosive reﬂux oesophagitis, treatment with
rabeprazole 10mgprn is less expensive than with either
20mg or 40mg esomeprazole prn. All three alternatives
are comparable in terms of their effectiveness.
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OBJECTIVES: To compare the costs and consequences 
of Enteryx with Laparascopic Nissen Fundoplication
(LNF) and pharmacological therapy (PPIs) in patients
with Gastro-Oesophageal Reﬂux Disease (GORD). The
Enteryx Procedure is a new endoscopically injected
polymer-based treatment for GORD. METHODS: A
decision analytical approach was taken to model the
ability of the three interventions to successfully treat
patients with GORD. The model time horizon was one
year with an additional 5-year long-term perspective. The
clinical outcomes and the resource consumption data 
for PPIs were derived from the literature. A multicentre
clinical study of Enteryx provided the clinical outcomes
for Enteryx. Treatment outcomes following LNF were
sourced from the literature. Experienced UK experts pro-
vided resource consumption data for the Enteryx proce-
dure and LNF. Patients on pharmacological treatment
(PPIs) with relapse followed the recommended route of
moving to higher dose therapy for eight weeks and if still
not responding received a further eight weeks followed
by an endoscopy. RESULTS: At 1-year average costs per
patient were lower with Enteryx (£2683) than with LNF
(£4718). The cost of PPI treatment at 1 year amounted
to £394 for all patients and to £691 for patients needing
a higher dose of treatment. At 5 years, Enteryx patients
had a lower cost of £3004 per patient compared to LNF
(£4769) and high dose PPI users (£3457). The average
cost for all PPI users at 5 years was £1970. CONCLU-
SIONS: For those patients suitable for surgery, Enteryx
provides a less expensive option than LNF largely due to
the reduced hospitalisation and procedure costs. Due to
the recurrent nature of PPI treatment and cost, Enteryx
is a cost saving therapy in the long-term compared to
pharmacological therapy, especially for patients on high
maintenance dose.
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OBJECTIVES: To estimate the cost of illness and the
disease burden, in terms of disability adjusted life years
(DALYs), for gastroenteritis in the Netherlands in 1999.
METHODS: The study population consisted of a com-
munity-based prospective cohort study on gastroenteritis,
with a nested case-control study, in cooperation with the
Dutch sentinel general practice network. Cases with gas-
troenteritis identiﬁed in the cohorts were requested to
submit stool samples, complete a questionnaire on risk
factors and complete a medical diary for four weeks. In
this diary, cases reported daily about symptoms, absence
from work or school, use of medication and use of health
services, such as GP and hospital services. Health services
use and productivity losses were valued according to
